Clinical Trials · NCT07673900
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Terrestrial Bio, Inc.
- Enrollment
- 62
- Start date
- Jun 2026
- Locations
- 1 site, United States
- Primary endpoint
- Type, incidence, and severity of treatment emergent adverse events (TEAEs), including assessment of application site skin sensitivity, vital signs, electrocardiograms (ECGs), and clinical laboratory results)